People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

“It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression.

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Research also suggests that esketamine nasal spray doesn’t affect thinking skills the way high doses of ketamine do. What’s Next Along with treatment-resistant depression, Spravato is approved ...